Vigil Neuroscience Enrolls First Subject in ALSP Study
September 15, 2021
Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced today the enrollment of the first subject in a natural history study dedicated to patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). ALSP is a rare, genetically defined fatal neurodegenerative disease with strong mechanistic and biochemical associations to microglia dysfunction.